The major causes of morbidity and mortality in sickle cell disease (SCD) are the acute and long-term consequences of vaso-occlusion and hemolysis, many of which This site uses
3 min read Reviewed by: HU Medical Review Board | Last reviewed: February 2023 Hydroxyurea has been used to treat sickle cell disease (SCD) since the 1980s
The introduction of hydroxyurea treatment with its reduction in morbidity and mortality, associated decreased medical costs, and restored well being should lead to
Background: Effective management of complications in sickle cell disease (SCD), such as stroke prevention, often necessitates the use of blood transfusions
With her patient
These children were followed for up to 3 years from 2012 to 2019
Sickle cell disease (SCD) is one of the most common inherited diseases worldwide
cell disease can also have problems with fertility due to their sickle cell disease
04 acute care visits per person-year in 2015 (P <
We herein present the clinical course of a patient prior to and after the initiation of hydroxyurea with an emphasis on long-term outcomes and the patterns of liver injury over a 15-year time Introduction
It is associated with lifelong morbidity and a reduced life expectancy
When you take hydroxyurea regularly, it helps your red blood cells stay round, flexible, and less likely to sickle
For female patients: Hydroxyurea has caused birth defects in studies of pregnant animals
The review was well conducted, but it was based on only two randomised studies and
This systematic review and meta-analysis aimed to evaluate the role of hydroxyurea in preventing organ morbidity
Hydroxyurea decreases ** Further long-term safety and efficacy data of hydroxyurea use in adults with sickle cell disease, demonstrating significant reduction in mortality with hydroxyurea exposure
The hallmark of SCD is chronic hemolytic Hydroxyurea: What You Need to Know
1365-2141
Affiliation 1 Department Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability
Hydroxyurea is an oral therapy initially approved for several types of cancer and later developed and used for sickle cell disease (SCD)